Indeed, immunohistochemistry in TUR specimens showed that patients with AR-positive or Rab27b-positive non-muscle-invasive bladder tumor subsequently undergoing BCG therapy had a significantly higher risk of postoperative disease recurrence, compared to those with AR/Rab27b-negative tumor. The gene discussed is AR; the disease is neoplasm.